![]() ![]()
Jonathan Lim, M.D., former co-founder and CEO of Ignyta, serves as the company’s Chairman. Hornby was previously Chief Operating Officer of Ignyta, Inc., from its inception through its acquisition and integration by Roche. Initial programs are directed to high copy number, focal gene amplification solid tumors, where ecDNA are believed to be a primary driver.īiotech veteran Zachary Hornby is President, Chief Executive Officer, and a Director of Boundless Bio. The funds raised will be used to cement a leadership position in the emerging field of ecDNA biology by continuing to build technology capable of identifying and characterizing ecDNA-driven tumors identifying and validating novel cancer targets and developing targeted, proprietary treatments that exploit ecDNA’s unique vulnerabilities. The financing round was co-led by ARCH Venture Partners and City Hill Ventures, with participation from Vertex Ventures, GT Healthcare Capital Partners, Boxer Capital of the Tavistock Group, Alexandria Venture Investments, and other undisclosed investors. The company’s joint lab and office headquarters is based in the biotech hotbed of the Torrey Pines region of San Diego, California. Boundless Bio is leveraging new discoveries about the role of ecDNA in driving cancer growth, resistance, and recurrence to develop the first ecDNA-targeting medicines and transform outcomes for patients with high copy number, focal gene amplification cancers, which historically have been very difficult to treat. #BOUNDLESS GAME STORAGE BLOCK SERIES#Retrieved October 23, 2021.SAN DIEGO-( BUSINESS WIRE)-Boundless Bio, a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the completion of a $46.4 million Series A financing.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |